Aquestive Therapeutics, Inc. Accounts Receivable, before Allowance for Credit Loss
Aquestive Therapeutics, Inc. (AQST) had Accounts Receivable, before Allowance for Credit Loss of $7.72 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-08-11
- 2026-06-30: Accounts Receivable, before Allowance for Credit Loss $7.72M.
- 2026-03-31: Accounts Receivable, before Allowance for Credit Loss $5.26M.
- 2025-12-31: Accounts Receivable, before Allowance for Credit Loss $8.01M.
- 2025-09-30: Accounts Receivable, before Allowance for Credit Loss $9.48M.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $7.72M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $5.26M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $8.01M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $9.48M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $9.65M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $8.31M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.92M 10-K · filed 2026-03-04 |
| 2024-09-30 | $7.71M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $4.33M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $6.70M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $5.57M 10-K · filed 2025-03-05 |
| 2023-09-30 | $6.85M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $7.97M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $4.12M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $3.27M 10-K · filed 2024-03-05 |
| 2022-09-30 | $9.36M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $16.24M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $18.62M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $9.68M 10-K · filed 2023-03-31 |
| 2021-09-30 | $11.50M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $9.63M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $8.13M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $4.33M 10-K · filed 2022-03-08 |
| 2020-09-30 | $6.66M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $11.81M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $8.47M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $9.09M 10-K · filed 2021-03-09 |
| 2019-09-30 | $9.69M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $10.04M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $7.33M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $6.61M 10-K · filed 2020-03-11 |
| 2018-09-30 | $7.51M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $6.66M 10-Q · filed 2018-09-04 |
| 2017-12-31 | $6.16M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |